Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cantharidin - Verrica Pharmaceuticals

Next Previous
Search
Drug Profile

Cantharidin - Verrica Pharmaceuticals

Alternative Names: Cantharidin 0.7% topical solution; TO-208; VP 102 - Verrica Pharmaceuticals; VP 103; VP 103 - Verrica Pharmaceuticals; VP-102; YCANTH

Latest Information Update: 26 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Verrica Pharmaceuticals
  • Developer Torii Pharmaceutical; Verrica Pharmaceuticals
  • Class Antivirals; Benzofurans; Epoxy compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Serine protease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Molluscum contagiosum
  • Phase II Genital warts; Warts

Most Recent Events

  • 11 Mar 2025 Verrica Pharmaceuticals plans a phase III trial for VP 102 for the treatment of Warts, by mid-2025
  • 28 Dec 2024 No recent reports of development identified for preclinical development in Warts in USA
  • 12 Dec 2024 Verrica pharmaceuticals plans a phase II trial for Warts (plantar warts) (Verrica pharmaceuticals pipeline, December 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top